biotickrNuvation Bio Inc
The NUVB stock trades on New York Stock Exchange Inc
Company Description
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Our vision is to significantly change the practice of oncology by developing medicines that provide truly meaningful improvements in quality of life and survival for people with cancer.
Our wholly-owned deep pipeline includes six differentiated and novel investigational oncology therapeutic candidates that target some of the most critical pathways that cancer cells use to grow. We were founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Our vision is to significantly change the practice of oncology by developing medicines that provide truly meaningful improvements in quality of life and survival for people with cancer.
Our wholly-owned deep pipeline includes six differentiated and novel investigational oncology therapeutic candidates that target some of the most critical pathways that cancer cells use to grow. We were founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Drug Pipeline
Source: Nuvation Bio Inc - 20220930
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
NUV-422
Breast Cancer
Phase 1
Metastatic Castration-Resistant Prostate Cancer
Phase 1
Recurrent Glioblastoma Multiforme
Phase 1
NUV-868
Metastatic Castration-Resistant Prostate Cancer
Preclinical
Ovarian Cancer
Preclinical
Pancreatic Cancer
Preclinical
Solid Tumors
Phase 1
Triple-Negative Breast Cancer
Preclinical
0 Comments on NUVB stock
Newest
Conversation